Kazia Therapeutics Ltd ADR (KZIA) Stock Analysis

Kazia Therapeutics Ltd ADR (KZIA) is a publicly traded company in the HEALTHCARE sector. It trades at $11.79, carries a market capitalization of $143.52M. This page summarizes the public market data, fundamentals, and frequently asked questions for KZIA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Kazia Therapeutics Ltd ADR currently has a Bullish sentiment score of 0.31.

About Kazia Therapeutics Ltd ADR

Kazia Therapeutics Ltd ADR is an innovative Australian biotechnology firm based in Sydney, primarily engaged in the development of advanced cancer therapies. The company is advancing its proprietary drug candidates through clinical trials, with a particular focus on addressing significant unmet needs in oncology, including treatments for brain cancer and other solid tumors. Its lead asset, GDC-0084, targets key pathways in cancer biology, aspiring to improve patient outcomes. With a strong co...

GNG Research Analysis

GNG Research scores Kazia Therapeutics Ltd ADR (KZIA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KZIA.

Frequently Asked Questions

Does KZIA pay dividends?

Kazia Therapeutics Ltd ADR (KZIA) does not currently pay a regular dividend.

What is KZIA's market cap?

Kazia Therapeutics Ltd ADR (KZIA) has a market capitalization of $143.52M with a current stock price of $11.79.